Bayer/Onyx BAY 43-9006 Interim Analysis To Support Accelerated NDA Filing
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Onyx expects its kidney cancer therapy BAY 43-9006 to receive accelerated approval by 2006 based on initial Phase III data showing statistically significantly longer progression-free survival versus placebo